FDA requires opioid labeling changes to help providers safely taper dosing
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels to provide expanded guidance to health care professionals on how to safely decrease or discontinue these medications in patients who are physically dependent on them. The agency said it has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased, a safety concern it continues to track.
Related News Articles
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…
Headline
While counseling and other services are an important part of a comprehensive treatment plan for opioid use disorder, the provision of medication should not be…
Headline
AHA today launched an updated Opioid Stewardship Hub, featuring the latest tools and resources to help hospitals and health systems address the opioid epidemic…
Headline
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and…